Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of May 21, 2026, AKTS trades at $19.04 with a market cap of $1.03B and a P/E ratio of -9.99. AKTS moved +3.03% today. Year to date, AKTS is +24873.80%; over the trailing twelve months it is flat. Its 52-week range spans $0.03 to $29.16. Analyst consensus is strong buy with an average price target of $33.50. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aktis Oncology, Inc. Common stock (AKTS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. AKTS moved +3.03% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $19.04 |
| Market Cap | $1.03B |
| P/E Ratio | -9.99 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.16 |
| 52-Week Low | $0.03 |
| Volume | 94.41K |
| Avg Volume | 0 |
| Revenue (TTM) | $27.38M |
| Net Income | $-167.95M |
| Gross Margin | -2.52% |
4 analysts cover AKTS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.50.